Table 9.

Kidney

Author	Cases N	Controlsa/Cohortb	Source Population	Exposure definition	Exposure assessment	Drug	RR	95% CI
McLaughlin et al. [63]	495*	697a	Population based	More than 14 times per month for >36 months	Personal Interview	Aspirin (8%)	0.5†	0.2–1.0
							1.8‡	0.7–4.1
McCredie et al. 1988[64]	360*	985a	Population based	>0.1 kg lifetime use	Mailed questionnaire	Aspirin (18%)	1.2	0.7–1.9
McCredie et al.1995[65]	1,732*	2,309a	Population based	>5 kg lifetime use	Personal Interview	Aspirin (5%)	1.2	0.9–1.7
Gago-Dominguez et al. [66]	1,201*	1,204a	Population based	Two or more times a week for 1 month or longer	Personal Interview	Aspirin (27%)	1.5	1.2–1.8
Paganini-Hill et al. [40]	NR*	13,987b	Cohort	Daily use of aspirin for an undefined time	Mailed Questionnaire	Aspirin (16%)	6.3	2.0–20.0
Schreinemachers et al. [43]	32	12,668b	Cohort	Ever use of aspirin in the 30 days prior to start date	Personal Interview	Aspirin (59%)	0.60	0.29–1.24

*Renal cell carcinoma only; Prevalence of exposure among controls/cohort; ^†Male only; ^‡Female only.